BridgeBio Pharma Ownership | Who Owns BridgeBio Pharma?
BridgeBio Pharma Ownership Summary
BridgeBio Pharma is owned by 97.37% institutional investors, 4.93% insiders. Kohlberg kravis roberts is the largest institutional shareholder, holding 13.40% of BBIO shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.56% of its assets in BridgeBio Pharma shares.
BBIO Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | BridgeBio Pharma | 97.37% | 4.93% | -2.30% |
Sector | Healthcare Stocks | 279.19% | 10.62% | -189.81% |
Industry | Biotech Stocks | 63.96% | 10.74% | 25.30% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Kohlberg kravis roberts | 25.26M | 13.40% | $693.16M |
Viking global investors lp | 25.12M | 13.33% | $689.32M |
Vanguard group | 15.08M | 8.00% | $413.74M |
Blackrock funding, inc. /de | 13.71M | 7.27% | $376.19M |
Blackrock | 12.45M | 6.64% | $315.31M |
State street | 6.18M | 3.28% | $169.65M |
Aisling capital management lp | 6.07M | 3.22% | $166.51M |
Janus henderson group | 4.91M | 2.60% | $134.67M |
Farallon capital management | 4.20M | 2.23% | $115.11M |
Laurion capital management lp | 3.74M | 1.98% | $102.65M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Aisling capital management lp | 6.07M | 59.08% | $166.51M |
Kohlberg kravis roberts | 25.26M | 18.56% | $693.16M |
Prosight management, lp | 995.00K | 7.55% | $27.30M |
Cutter capital management, lp | 560.34K | 6.30% | $15.38M |
Superstring capital management lp | 262.14K | 6.23% | $7.19M |
Lion point capital, lp | 40.30K | 5.79% | $1.11M |
Exome asset management | 246.70K | 5.09% | $6.77M |
Sphera funds management | 905.28K | 4.49% | $24.84M |
Frazier life sciences management | 3.63M | 4.30% | $92.01M |
Adar1 capital management | 678.86K | 3.72% | $18.63M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Farallon capital management | 4.20M | 0.58% | 2.45M |
Blackrock | 12.45M | 0.01% | 1.98M |
Woodline partners lp | 2.21M | 0.41% | 1.26M |
Norges bank | 1.07M | 0.00% | 1.07M |
Capital research global investors | 3.53M | 0.02% | 912.44K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Lord, abbett | - | - | -2.80M |
Perceptive advisors | - | - | -1.22M |
Paradigm biocapital advisors lp | - | - | -1.09M |
Hhlr advisors | - | - | -1.02M |
Pictet asset management sa | 1.81M | 0.05% | -995.59K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Norges bank | 1.07M | 0.00% | 1.07M | $29.24M |
Deep track capital, lp | 819.16K | 0.84% | 819.16K | $22.48M |
Pfm health sciences, lp | 290.24K | 0.49% | 290.24K | $7.96M |
Susquehanna fundamental investments | 238.00K | 0.09% | 238.00K | $6.53M |
Balyasny asset management | 207.28K | 0.01% | 207.28K | $5.25M |
Sold Out
Holder | Change |
---|---|
Financial gravity asset management | -3.00 |
Creekmur asset management | -3.00 |
Pfg private wealth management | -11.00 |
Colonial trust advisors | -22.00 |
Nelson, van denburg & campbell wealth management group | -22.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Mar 31, 2025 | 344 | 12.05% | 185,144,507 | 4.79% | 97 | 1.11% | 196 | 24.05% | 82 | 5.13% |
Dec 31, 2024 | 304 | 8.57% | 172,882,432 | 0.83% | 91 | 1.11% | 155 | 6.90% | 78 | 1.30% |
Sep 30, 2024 | 278 | -2.11% | 171,231,529 | -1.98% | 90 | 1.05% | 147 | -3.29% | 74 | 2.78% |
Jun 30, 2024 | 284 | 1.43% | 174,683,428 | 2.52% | 93 | 1.02% | 152 | 11.76% | 72 | -15.29% |
Mar 31, 2024 | 280 | 3.32% | 170,388,909 | 3.05% | 95 | 0.92% | 136 | -5.56% | 85 | 8.97% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
Vanguard Total Stock Mkt Idx Inv | 4.87M | 2.56% | 13.92K |
Vanguard US Total Market Shares ETF | 4.53M | 2.38% | 3.92K |
Vanguard Small Cap Index | 3.82M | 2.01% | 26.97K |
iShares Russell 2000 ETF | 3.59M | 1.89% | 1.76K |
American Funds SMALLCAP World A | 2.67M | 1.40% | 204.74K |
SPDR® S&P Biotech ETF | 2.28M | 1.20% | 2.95K |
Vanguard Institutional Extnd Mkt Idx Tr | 2.28M | 1.20% | 10.54K |
Vanguard Small Cap Growth Index Inv | 2.13M | 1.12% | -3.00K |
Capital Group New Economy Comp | 1.56M | 0.82% | 883.59K |
American Funds New Economy A | 1.56M | 0.82% | 883.59K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Jun 10, 2025 | Valantine Hannah | - | Sell | $171.68K |
May 19, 2025 | Kumar Neil | Chief Executive Officer | Sell | $13.50K |
May 20, 2025 | Kumar Neil | Chief Executive Officer | Sell | $2.50M |
May 19, 2025 | Kumar Neil | Chief Executive Officer | Sell | $858.26K |
May 12, 2025 | KKR Genetic Disorder L.P. | - | Sell | $205.20M |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q2 | - | 10 |
2025 Q1 | - | 15 |
2024 Q4 | - | 3 |
2024 Q3 | - | 5 |
2024 Q2 | - | 3 |
BBIO Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools